ARTICLE | Company News
Somerset submits NDA
May 25, 2001 7:00 AM UTC
Somerset (Tampla, Fla.) submitted an NDA to the FDA for Emsam selegiline transdermal inhibitor of MAO-B enzyme to treat depression. Selegiline is marketed as an adjunct therapy for Parkinson's disease...